Clinical significance of serum anti-granulocyte–macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis

Table 1 Clinical characteristics of patients

Variables	Healthy controls	aPAP	Sarcoidosis	HP
N	31	110	92	45
Age, [IQR] years	56 [55, 59]	56 [46, 65]	59 [38, 70]	61 [53, 70]
Male, n [%]	15 [48.3]	77 [70]	39 [42.3]	24 [53.3]
Complication of aPAP, n [%]	–	–	2 [2.1]	1 [2.2]
GMAb [IQR] μg/mL	0.85 [0.52, 1.06]	40.5 [17.1, 71.8]	0.43 [0.16, 0.85]	0.87 [0.54, 1.10]

Data are expressed as the median [IQR] or number [%]
aPAP autoimmune pulmonary alveolar proteinosis, HP hypersensitivity pneumonitis, GMAb anti-granulocyte–macrophage colony-stimulating factor autoantibody

ISSN: 1750-1172